This is USFDA's 23rd warning letter to an Indian drugmaker in the last eleven months, and third for the Gujarat-based Torrent Pharma. Previously, the company received warnings in July and October this year for its manufacturing facilities in Dahej and Indrad.
I was on piratebay and downloaded a couple of movies. I get an email from my internet provider informing me that. Dear Spectrum Internet Subscriber: Charter Communications ("Charter") has received a notice from a copyright owner, or its authorized agent, that your Internet account may have been involved in the exchange of unauthorized copies of copyrighted material (e.g., music, movies, or Read more about Torrent Pharma gets warning letter from USFDA for Gujarat facility on Business Standard. Drug firm Torrent Pharmaceuticals on Wednesday said it has received a warning letter from the US health regulator for its Indrad facility in Gujarat.This action by the United States Food and Drug Administration (USFDA) follows earlier intimation For District Office Warning Letters see the Main FDA FOI Warning Letters Page. Some of the letters have been redacted or edited to remove confidential information. Matters described in FDA warning Drug firm Torrent Pharmaceuticals on Wednesday said it has received a warning letter from the US health regulator for its Indrad facility in Gujarat. This action by the United States Food and Drug
Read more about Torrent Pharma gets warning letter from USFDA for Gujarat facility on Business Standard. Drug firm Torrent Pharmaceuticals on Wednesday said it has received a warning letter from the US health regulator for its Indrad facility in Gujarat.This action by the United States Food and Drug Administration (USFDA) follows earlier intimation
FDA sent a warning letter, dated Oct. 28, 2019, to Torrent Pharma after an inspection of the company's Levittown, PA facility found deviations from current good manufacturing practices.During the inspection, which was conducted from March 11-April 9, 2019, FDA investigators found that the company's water system was inadequate, and it had failed to properly investigate failing
Last week, Torrent Pharma had informed stock exchanges that the US FDA has issued a warning letter to its Indrad plant following an inspection of the facility in April.
FDA sent a warning letter, dated Oct. 28, 2019, to Torrent Pharma after an inspection of the company's Levittown, PA facility found deviations from current good manufacturing practices.During the inspection, which was conducted from March 11-April 9, 2019, FDA investigators found that the company's water system was inadequate, and it had failed to properly investigate failing NEW DELHI: The US Food and Drug Administration (FDA) issued a warning letter to Torrent Pharmaceuticals Ltd's Indrad plant in Gujarat on Tuesday following an inspection of the facility in April Warning Letters 2018. These letters are supplied by the CDER Freedom of Electronic Information Office. This page only covers Office of Prescription Drug Promotion (formerly Division of Drug Home; Business; US FDA issues warning letters to Glenmark, Torrent; US FDA issues warning letters to Glenmark, Torrent According to the letter issued to Glenmark, the company "failed to adequately investigate more than 70 consumer complaints associated with punctures, cracks, and holes" in some of the topical creams and ointments manufactured at its Baddi facility. Torrent Pharma gets warning letter from USFDA for Gujarat facility. The company does not believe that the warning letter will have an impact of disruption of supplies or the existing revenues from